Researchers identify ‘switch’ to activate cancer cell death::undefined

  • @[email protected]
    link
    fedilink
    English
    321 year ago

    Yeah and let’s pile it up on all the other ones we already found.

    Don’t get me wrong, it’s cool that research goes on, but please stop lying in the headlines.

    This new ability to trigger programmed cell death could open the door for improved cancer treatments.

    This. This is the headline.

    BTW cancer replicates so fast, in a shitty environment (not enough food for example, need to replicate too fast) so its usually mutate like a lot, so this treatment will kill off all original cancerous cells (say 600.000.000 …), but not those three that evade this specific treatment (and the other treatments) and they’ll just double every X milliseconds and continue the work.

    It is good though, that there are new treatments coming.

    IMO the best one today is still our immune system, we don’t get lots of cancers at 20, but we tend to do at 70. Sure, that’s also because of lots of other things basic aging has done to us, not only aged the immune system, but still, I think curing, or just reversing or if you want, repairing (damage done by) aging is one of the most important goals not just in biogerontology but in biology and medicine in general.

    Cheers

    • ThoGot
      link
      fedilink
      English
      21 year ago

      Wouldn’t you have to somehow preserve your genome better than your cells already do it themselves to prevent aging / mutations

      • @[email protected]
        link
        fedilink
        English
        21 year ago

        Sure, but there are also lots of gene-repair systems already in place. Some animals have lots (more than us) and have way less point mutations etc.

        Also, as long as we can buy ourselves some extra decades, new tech will emerge and work even better.

  • @asbestos
    link
    English
    141 year ago

    pharmaceutical companies: where’s the switch to activate cancer? asking for a friend 😎

  • @[email protected]
    link
    fedilink
    English
    111 year ago

    This article is worth reading if only for this line:

    However, though drug companies have had some success targeting the Death Receptor-5, no Fas agonists have made it into clinical trials.